Efficacy of combination therapy IFN-alpha-2b and ribavirin for patients with Serogroup2 and high titer HCV / without Serogroup1 and high titer HCV.

Efficacy of combination therapy IFN-alpha-2b and ribavirin for patients with Serogroup2 and high titer HCV / without Serogroup1 and high titer HCV. - Combination therapy of IFN-alpha-2b and ribavirin. (Serogoup2 and high titer) (Not serogoup1 and high titer)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000196

Enrollment

200

Registered

2008-12-31

Start date

2004-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

24weeks treatment with IFN-alpha-2b plus ribavirin 24weeks treatment with IFN-alpha-2b plus ribavirin and 24weeks tretment with IFN-alpha-2b 24weeks treatment with IFN-alpha-2b plus ribavirin 24weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CHC(Serogroup2 and high titer) CHC(Not serogroup1 and high titer)

Exclusion criteria

Exclusion criteria: Pregnant or lactating women and women who may be pregnant Female patients or male patients with partners who may become pregnant who cannot practice contraception during treatment and 6 months after end of treatment Male patients with pregnant partners who cannot comply with condom use during treatment and 6 months after end of treatment History of hypersensitivity to ribavirin or other nucleoside analogs Inadequately controlled cardiac disease Hemoglobinopathy Chronic renal failure or renal function disorder with creatinine clearance of 50 ml/min or less With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. Serious hepatic function disorder Autoimmune hepatitis History of hypersensitivity to IFN alfa-2b or other interferons History of hypersensitivity to biological products such as vaccine Patients receiving shosaikoto Judged by investigator to be not appropriate for inclusion in study

Design outcomes

Primary

Measure	Time frame
Efficacy of combination therapy IFN-alpha-2b and ribavirin for CHC with advanced fibrosis Efficacy of low-dose IFN therapy for intractable CHC Efficacy of ribavirin early dose down reguration for CHC	—

Countries

Japan

Contacts

Public ContactRyotaro Sakamori

Osaka university graduate school of medicine Gastroenterology and Hepatology

sakamori@gh.med.osaka-u.ac.jp81-6-6879-3621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026